Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607570 | 0.82 | TSHR (0.55) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL4732973 | 0.81 | EPHX2 (0.61) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL28611807 | 0.79 | ALDH1A1 (0.54) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL27415157 | 0.79 | ALDH1A1 (0.54) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL31162224 | 0.77 | EPHX2 (0.48) | EPHX2ALDH1A1TDP1KDM4E | |
| SCHEMBL18656011 | 0.77 | EPHX2 (0.49) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL21603977 | 0.76 | TSHR (0.40) | TSHRKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL21577641 | 0.76 | EPHX2 (0.57) | EPHX2STSKMT2AMEN1ALDH1A1 | |
| SCHEMBL19331972 | 0.75 | EPHX2 (0.48) | TSHREPHX2STSKMT2AMEN1 | |
| SCHEMBL28623458 | 0.73 | STS (0.44) | EPHX2STSKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | TSHR 2289/4885EPHX2 1603/4885STS 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.